MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On July 31, 2017, Medovex Corp. (the “Company”) received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (the “Panel”) notifying the Company that the Panel had determined to allow the Company to remain listed on the NASDAQ Capital Market. The Company’s continued listing on NASDAQ is subject to the Company advising the Panel of developments related to its Capital raising efforts and providing certain financial projections by October 15, 2017 and the Company showing that it has stockholders’ equity of over $2.5 million by November 13, 2017 or it faces potential delisting.
The Company expects to continue to exercise diligent efforts to maintain the listing of its common stock on NASDAQ. As such, the Company intends to continue to timely provide NASDAQ with any and all required materials to maintain its listing. While confident in already ongoing initiatives which the Company believes will provide a sustainable solution to maintaining compliance with NASDAQ Listing Rule 5550(b)(I) related to stockholders equity, the Company must advise investors that there can be no reasonable assurance that the Company will be able to maintain compliance.
